INGN Inogen Inc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1294133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.7%
TTM net income YoY-39.7%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin39.6%
Operating margin-10.4%
Net margin-9.3%
FCF margin-3.0%
EBITDA margin-4.2%
Returns
ROE-20.0%
ROA-12.4%
ROIC (approx.)-37.5%
Asset turnover1.33x
Leverage & solvency
Liabilities / assets40.7%
Debt / equity0.00x
Current ratio2.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $348.67M | $335.70M |
| Cost of revenue | $194.40M | $180.96M |
| Gross profit | $154.26M | $154.74M |
| R&D expense | $19.40M | $21.61M |
| SG&A expense | $67.38M | $72.58M |
| Operating income | -$30.21M | -$42.52M |
| Pretax income | -$23.38M | -$36.48M |
| Income tax | -$632,000 | -$588,000 |
| Net income | -$22.75M | -$35.89M |
| EBITDA | -$9.55M | -$21.51M |
| EPS (basic) | -0.86 | -1.52 |
| EPS (diluted) | -0.86 | -1.52 |
| Weighted avg. shares (diluted) | 26.60M | 23.65M |
| Balance sheet | ||
| Cash & equivalents | $103.73M | $113.80M |
| Short-term investments | $15.85M | $0 |
| Receivables | $34.14M | $29.56M |
| Inventory | $25.97M | $24.81M |
| Current assets | $224.60M | $185.45M |
| PP&E, net | $10.06M | $44.40M |
| Goodwill | $10.70M | $9.46M |
| Intangibles | $30.76M | $30.49M |
| Total assets | $298.62M | $296.19M |
| Current liabilities | $63.53M | $76.69M |
| Total liabilities | $106.39M | $122.33M |
| Shareholders' equity | $192.23M | $173.86M |
| Shares outstanding | 27.23M | 23.90M |
| Cash flow statement | ||
| Operating cash flow | -$11.22M | $5.91M |
| Capital expenditure | $2.52M | $3.36M |
| Free cash flow | -$13.74M | $2.55M |
| Investing cash flow | -$26.21M | -$13.97M |
| Financing cash flow | $24.18M | $265,000 |
| Depreciation & amortization | $20.66M | $21.00M |
| Stock-based compensation | $8.01M | $7.40M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.